Pfizer, Inc.(PFE) - Stock detail

Pfizer, Inc.

US
PFE
Pfizer Inc.(Listing date: 01/17/1944)

Pfizer Inc. was incorporated under the laws of Delaware on June 2, 1942. It is a research-based global biopharmaceutical company. Using science and global resources, the company brings therapies that extend and significantly improve people's lives through the discovery, development, manufacturing and distribution of healthcare products, including innovative medicines and vaccines. The company operates in both developed and emerging markets, committed to advancing health, prevention, treatment and cure for the world's most feared diseases of our time. It collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare services worldwide.

AI Value AnalystHold
Overall Rating4.7/10
Generated at:2026-04-17 17:41:55
Analysis based on real data. A total of 5 financial reports were used for financial analysis, covering periods up to 2025-12-31. Real-time price data as of 2026-04-18.
Overview

Pfizer, Inc. (PFE) is a leading global biopharmaceutical company with a robust product portfolio and pipeline. The fundamental analysis reveals a mixed picture: the company is financially stable with reasonable valuation, but faces headwinds including declining revenue and net income, modest returns on capital, and tight liquidity ratios. The stock appears to be trading close to its fair value without a compelling margin of safety.

Valuation
5/10
Profitability
4/10
Financial health
5/10
Operation Advice
  • Existing shareholders should Hold.
  • New investors might consider initiating a position on meaningful price weakness or upon signs of a sustained turnaround in revenue growth.
  • The fundamental-based target price is $28.50, slightly above the current price of $27.56.

Valuation

P/E TTM
19.48
P/E LYR
18.50
P/B MRQ
1.75
P/S TTM
--
AI Analysis
  • Valuation metrics suggest the stock is trading close to fair value. The P/E of 19.48x (TTM) and P/B of 1.75x are reasonable for a large-cap pharmaceutical company. The current price falls within the calculated fundamental valuation range of $21.76 to $29.92.
  • Current Price: $27.56 (as of 2026-04-18).
  • P/E (TTM): 19.48x. This is based on trailing twelve-month earnings.
  • Forward P/E (Dynamic): 18.50x. This suggests a slight expectation of earnings growth or stability.
  • A P/E in the high teens is not excessively high for a large-cap pharmaceutical company, especially one with a strong dividend history.
  • Price-to-Book (P/B): 1.75x. This indicates the market values the company at a 75% premium to its book value.
  • Price-to-Sales (P/S): 2.51x. This multiple is moderate for the pharmaceutical industry.
  • Based on a normalized P/E range of 16x to 22x and the 2025 Diluted EPS of $1.36, a fundamental earnings-based valuation range is $21.76 to $29.92.
  • Considering the current price of $27.56 sits within this range, near the upper half, the stock appears to be trading close to its fair value.
  • Fundamental-based Target Price: $28.50. This target reflects a slight premium to the current price.
Valuation trend

Profitability

ROE TTM
8.90%
Net margin
12.48%
Gross margin
74.33%
Total revenue
62.58B
AI Analysis
  • Profitability has been under pressure with declining revenue and net income. Gross margins remain robust, but net margins are impacted by high operating expenses. Return on equity and assets are modest.
  • For the full year 2025, revenue declined by 1.65% to $62.58B.
  • Net income attributable to shareholders declined by 3.24% to $7.77B.
  • This follows a strong rebound in 2024 (279% net income growth), which was likely driven by pandemic-related products.
  • The return to a decline suggests a post-pandemic normalization phase.
  • Gross margin remains robust at 74.33% (2025 annual), highlighting the high-margin nature of its pharmaceutical products.
  • Net margin of 12.48% indicates significant operating expenses, including R&D and SG&A.
  • Return on Equity (ROE) of 8.90% and Return on Assets (ROA) of 3.69% are modest.
  • An ROE below 10% is generally not considered strong, suggesting the company is generating a relatively low return on shareholder capital.
Profitability
2024Q42025Q12025Q22025Q32025Q4
ROE TTM9.06%3.32%----8.90%
Earnings
2024Q42025Q12025Q22025Q32025Q4
Total revenue63.63B13.71B----62.58B

Financial health

Debt/Asset
58.31%
Current ratio
1.16
Quick ratio
0.87
Cash ratio
0.87
AI Analysis
  • Financial health shows a mixed picture. The company has sufficient liquidity but with a thin margin of safety. Leverage is at a moderate and manageable level for the industry.
  • The current ratio of 1.16 indicates the company has sufficient current assets to cover its current liabilities, though it is not a large margin of safety.
  • The quick ratio of 0.87 (below 1.0) suggests a reliance on inventory to meet short-term obligations, which is common for a manufacturing company but warrants monitoring.
  • The debt-to-asset ratio of 58.31% indicates a moderate level of financial leverage.
  • This is a manageable level for a large, cash-generative pharmaceutical company but does imply a significant portion of assets are financed by debt.
  • The company is not in immediate financial distress, but its liquidity metrics are not strong.
  • The leverage is acceptable for the industry but requires consistent profitability to service comfortably.
Leverage
2024Q42025Q12025Q22025Q32025Q4
Debt/Asset58.53%56.43%----58.31%
Liquidity
2024Q42025Q12025Q22025Q32025Q4
Current ratio1.171.26----1.16